November 4, 2022, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that it rec

October 28th, 2022, Beijing -- Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company will participate i

On September 24, the handover ceremony of the Chinese government's donation of COVID-19 vaccine to Egyptian women, children, and adolescents & the delivery ceremony of SINOVAC's sponsored

October 21, 2022, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that the Co

SINOVAC's quadrivalent influenza vaccine collaborated with a local partner has been approved by the Directorate General of Drug Administration (DGDA) in Bangladesh for marketing use recently. This

September 6, 2022, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Chilean

August 25, 2022, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Chilean P

August 20, 2022, Beijing – Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the Qual

August 3, 2022, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that based on relat

July 19, 2022, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that a phase III cli

July 14, 2022, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that its COVID-19 va

HONG KONG--A kick off ceremony was held at Gleneagles Hospital Hong Kong (Gleneagles or GHK) for initiating a clinical trial to assess the safety and immunogenicity of the SINOVAC’s Omicron-specific C

Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the South African Health Products R

BEIJING--SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received the World Heal

On May 20, 2022, the Public Health Institute of Chile (ISP) released the fourth statistical report "AEFIs after the administration of SARS-CoV-2 vaccines in Chile in the pediatric and adolescent

May 9, 2022 – Jakarta, Indonesia – SINOVAC Biotech Ltd., (SINOVAC), a leading provider of biopharmaceutical products in China, has been honored with the "MITRA BUMN GLOBAL CHAMPION 2022" awa

BEIJING, China--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2021 annual report on Form 20-F with the U.S.

April 26, 2022, Sinovac Biotech Ltd. (“SINOVAC”) announced that its inactivated COVID-19 vaccine (Omicron strain) has been approved for clinical trial in China. SINOVAC continuously carried out the de

April 14, 2022, Sinovac Biotech Ltd. (“SINOVAC”) announced that its inactivated COVID-19 vaccine (Omicron strain) has been approved for clinical trial in Hong Kong, China. SINOVAC continuously carrie

A study of University of Hong Kong revealed that three shots of CoronaVac offered appromixtely 98% protection against death or severe illness in those over 60 years old, underscoring the importance of